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AbstrAct
Hepatocellular carcinoma (HCC) is characteristically one of the most rapidly 
proliferating tumors which outgrows functional blood supply and results in regional 
oxygen deprivation. Overexpression of PIM1, a serine/threonine kinase, has been 
identified recently in human cancers. Knowledge on PIM1 in HCC is however, 
scarce. By immunohistochemical analysis on 56 human primary HCC samples, we 
observed overexpression of PIM1 in 39% of the cases. In two independent cohorts 
of paired primary and extra-hepatic metastatic HCC tissues, PIM1 expression was 
higher (p=0.002) in the extra-hepatic metastatic HCC tissues as compared with 
the corresponding primary HCCs. PIM1 was markedly up-regulated in multiple HCC 
cell lines in hypoxic condition (1% O2) versus normoxia (20% O2). Silencing of 
PIM1 suppressed HCC cell invasion in vitro as compared to non-target control, and 
decreased HCC cell proliferation in vitro and tumor growth and metastatic potential 
in vivo. Knockdown of PIM1 significantly reduced glucose uptake by HCC cells and 
was associated with decreased levels of p-AKT and key molecules in the glycolytic 
pathway. Taken together, PIM1 is up-regulated by hypoxia in HCC and promotes 
tumor growth and metastasis through facilitating cancer cell glycolysis. Targeting 
PIM1 may have potential role in the management of HCC.
INtrODUctION
Hepatocellular carcinoma (HCC) is one of the 
most malignant cancers worldwide and highly prevalent 
in China and Southeast Asia. Characteristically, HCC is 
rapidly proliferating and often outpaces its functional 
blood supply, leading to regional oxygen deprivation and 
resulting in frequent intratumoral hypoxia. Furthermore, 
HCC palliative therapies (transarterial [chemo]
embolization [TACE/TAE]) that involve restriction of 
blood flow to the tumor bulk induce severe hypoxia. The 
major mechanism by which HCC cells adapt to hypoxia 
is through induction of the transcription factor, hypoxia 
inducible factor (HIF) [1]. O2 acts as a substrate for the 
prolyl hydroxylation of HIF-1/2α [2], which subsequently 
enables Von-Hippel-Lindau (VHL) to mediate ubiquitin-
proteasomal degradation [3]. Therefore, inhibition of 
propyl hydroxylase (PHD) by dimethyloxalylglycine 
(DMOG) could stabilize HIF-1/2α expression under 
normoxic condition. 
In human cancers, the hypoxic tumor 
microenvironment has been widely studied and is 
recognized as an important condition driving cancer 
metastasis [4]. In HCC, HIF-1α and HIF-2α were 
consistently found to be over-expressed in tumor tissues 
[5, 6]. Moreover, expression of vascular endothelial 
growth factor (VEGF), a well-characterized HIF target, is 
associated with poor prognosis in HCC patients [5].
PIM1 belongs to a group of constitutively 
activated serine/threonine kinases firstly identified as the 
Proviral integrating site for Moloney murine leukemia 
virus, which is a cause of murine leukemia [7, 8]. The 
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three members in the PIM family, PIM1 (chromosome 
6), PIM2 (chromosome X) and PIM3 (chromosome 
22), physiologically mediate cytokine signaling of 
hematopoietic cells [9]. In neoplastic conditions, PIM1 and 
PIM2 are involved in the oncogenesis of acute myeloid 
leukemia [10]. Knowledge on PIM1 in solid cancers has 
been emerging in recent years. PIM1 was found to be 
overexpressed in gastric [11] and prostate cancers [12], 
which was associated with aggressive clinicopathological 
features. 
Notably, hypoxia is one of the mechanisms 
regulating PIM1 expression. PIM1 was induced by 
hypoxia in pancreatic cancer cell lines, in which PIM1 
is stabilized by hypoxia by preventing it from ubiquitin-
mediated proteasomal degradation [13]. Apart from 
hypoxia, microRNAs such as miR33a were found to 
regulate PIM1 expression at post-transcriptional level 
[14]. Heat shock proteins (HSP) alter PIM1 expression by 
post-translational mechanisms. Binding to HSP70 induces 
ubiquitylation and proteasomal degradation of PIM1, 
while heat shock protein 90 (HSP90) protects PIM1 from 
proteasomal degradation [15, 16]. 
Although PIM1 is the founding member of the 
PIM family, the role of PIM1 in HCC remains elusive. 
In this study, we aimed to address the key questions on 
the expression pattern of PIM1 in HCC, the regulatory 
mechanism of PIM1 expression with special reference 
to hypoxia, and the functional characterization of PIM1 
in HCC. We found that PIM1 was overexpressed in 
primary HCCs and the expression level was higher 
in the extra-hepatic HCC metastatic tissues than the 
primary tumors. Silencing of PIM1 inhibited HCC 
proliferation and invasion in vitro and tumor growth and 
metastasis in vivo. PIM1 expression was up-regulated 
under hypoxic conditions mainly by inhibition of 
proteasomal degradation in a HIF-1α independent manner. 
Furthermore, PIM1 reprogramed HCC metabolism and 
facilitated tumor cell glycolysis, which in turn sustained 
tumor growth and enhanced tumor invasion. 
rEsULts
PIM1 is overexpressed in primary and metastatic 
Hcc tissues
By immunohistochemical analysis (whole-section) 
in 56 human HCC samples, 22 (39%) cases showed PIM1 
overexpression in primary HCC tissues as compared to 
the corresponding non-tumorous (NT) liver tissues (Figure 
1A). Overexpression is defined by cytoplasmic and/or 
nuclear staining in HCC tumor cells but not in the adjacent 
non-tumoral liver cells. In the clinical samples, moderate 
to strong nuclear and cytoplasmic staining was observed 
in the HCC tissues; while all NT tissues did not show 
specific staining. The clinicopathological parameters and 
the staining pattern were detailed in Supplementary Table 
S1. We also tested the immunoexpression of cirrhotic 
liver tissues not associated with tumors, and none showed 
positive staining in the hepatocytes (Supplementary Figure 
1). With additional immunohistochemical staining for 
Carbonic Anhydrase 9 (CA9) and Glucose Transporter 
1 (GLUT-1), both being well known HIF targets, in the 
primary HCC samples, we observed expression of CA9 
and/or GLUT-1 in HCC tissues in majority (20/22) of the 
PIM1-positive cases (Figure 1B). To further determine the 
clinical significance of PIM1 expression in HCC tissues, 
we examined PIM1 immunoexpression in a separate 
independent set of 19 paired primary and extra-hepatic 
HCC tissues (whole-section) to explore the potential role 
of PIM1 in HCC metastasis (Table 1). Among these 19 
cases, PIM1 expression was found in 11 (57.9%) primary 
HCC tissues and 18 (95%) metastatic HCC tissues, 
respectively (Figure 1C). Notably, in 7 (37%) of the 
19 cases, PIM1 was negative in the primary HCCs but 
positive in the corresponding metastatic tissues. We further 
extended the immunohistochemical analysis on 24 pairs of 
primary and metastatic tissues in a tissue microarray. Four 
(17%) and 12 (50%) cases were found to express PIM1 
in the primary and metastatic tissues respectively. The 
expression rate was lower than that from the whole section 
cohort most probably as a result of sampling error in a 
tissue microarray setting. However similarly, a significant 
proportion of cases (9/24; 37.5%) showed negative PIM1 
immunostaining in the primary tissues but positive staining 
in the metastases. PIM1 expression is significantly higher 
in metastatic HCC tissues than in the primary combining 
results from the two cohorts (p=0.002), which suggests 
that PIM1 may be up-regulated in the metastatic process 
of HCC. A similar significant result was still obtained 
after eliminating some cases in the two cohorts with a 
longer time interval between the resection of primary and 
metastatic tumors. The clinicopathological parameters 
and the staining pattern of the two paired primary and 
metastatic cohorts were detailed in Supplementary Table 
S2.
silencing of PIM1 inhibits tumor growth and 
metastasis in vivo 
In light of the expression pattern of PIM1 by 
immunohistochemical analysis, we next investigated 
the tumorigenicity of PIM1 in vivo by comparing the 
tumor growth using PIM1 knockdown approach. Based 
on the endogenous expression of PIM1 in HCC cells 
lines, we established PIM1 stable knockdown clones 
in SMMC-7721 and MHCC-97L cell lines (Figure 2Ai 
& Supplementary Figure 2). The knockdown effect 
was specific for PIM1 but not for PIM2 and PIM3 as 
demonstrated by qPCR (Supplementary Figure 3). Using 
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Figure 1: (A) Expression of PIM1 in HCC tissues by immunohistochemistry. PIM1 was overexpressed in HCC. Positive nuclear 
and cytoplasmic staining was observed in the HCC tumors. No staining was present in the corresponding non-tumorous (NT) tissues. (B) 
Immunohistochemical staining of PIM1 and CA9 in HCC tissues. (C) PIM1 immunohistochemical expression in paired primary and extra-
hepatic metastatic HCC tissues. Left panel - PIM1 staining was negative in the primary HCC tissue but was positive in the corresponding 
metastatic HCC tissue in the omentum; Right panel - PIM1 staining was positive in both primary HCC and the corresponding metastatic 
HCC tissue in the lymph node. 
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subcutaneous injection of tumor cells in nude mice, 
knockdown of PIM1 in both HCC cell lines significantly 
reduced the tumor growth in vivo (Figure 2Aii) in SMMC-
7721 and MHCC-97L cell lines, respectively, as compared 
with their NTC (p=0.003 and 0.036 for SMMC-7721 
and MHCC-97L, respectively). To examine the effect of 
the metastatic enhancing ability of PIM1 on HCC cells 
in a more physiological environment, orthotopic liver 
implantation model was employed using MHCC-97L 
cell line, a metastatic HCC cell line. The tumor-forming 
incidence was lower in PIM1 stable knockdown clone 
(1/4), as compared with NTC (4/4). The corresponding 
incidence of lung metastasis was also lower in PIM1 stable 
knockdown clone (Figure 2B).
Hypoxia induces expression and nuclear 
translocation of PIM1 protein in Hcc cells 
Since hypoxia can drive cancer metastasis [4], the 
expression of PIM1 in HCC cell lines in normoxic (20% 
O2) and hypoxic (1% O2) conditions were analyzed. 
In normoxia, PIM1 was expressed at variable levels in 
PLC/PRF/5, BEL-7402, SMMC-7721 and MHCC-97L 
cell lines upon Western blot analysis. When the HCC 
cells were exposed to the hypoxic condition, the PIM1 
expression was markedly up-regulated in all these cell 
lines, while the immortalized normal liver cell line MIHA 
did not express PIM1 whether under normoxia or hypoxia 
(Figure 3A).
With immunohistochemistry on the clinical HCC 
samples, we observed both nuclear and cytoplasmic 
staining in the HCC cells. Besides, nuclear translocation of 
Figure 2: silencing of PIM1 suppressed the tumor volume and metastatic ability in vivo. (A) i) Quantitative PCR analysis 
of PIM1 expression in NTC and PIM1 stable knockdown clones in SMMC-7721 (shPIM1-5) and MHCC-97L (shPIM1-4), respectively. 
ii) Subcutaneously inoculation of NTC and shPIM1-5 (SMMC-7721) or shPIM1-4 (MHCC-97L). Tumor growth volume upon inoculation 
measured with calipers; tumors were excised from the two groups of mice. (B) i) Xenogen imaging of nude mice orthotopically implanted 
with tumors derived from MHCC-97L-NTC and shPIM1-4 at 6th week upon implantation, with tumor incidence rate indicated. Livers from 
the two groups of mice at 6th week upon implantation, with tumor volume indicated respectively. ii) Ex-vivo imaging of lung from the two 
groups of mice, with pulmonary metastasis rate indicated. 
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PIM1 in hypoxia was reported in pancreatic cell lines [17]. 
Therefore, we performed cell fractionation and Western 
blotting to examine the subcellular localization of PIM1 
protein in normoxia and hypoxia. We observed that in 
normoxia, PIM1 was located in both the cytoplasm and 
nuclei of HCC cells, whereas hypoxia markedly enhanced 
nuclear translocation of PIM1 protein (Supplementary 
Figure 4). 
Up-regulation of PIM1 in hypoxia is HIF-1α-
independent and partly mediated by proteasomal 
degradation pathway
To interrogate whether hypoxia induction of 
PIM1 occurred at transcriptional, post-transcriptional, 
translational or post-translational level, we performed 
a time-point experiment to examine the PIM1 protein 
expression in HCC cells exposed to hypoxia and compared 
with that of HIF-1α. Up-regulation of PIM1 protein 
expression occurred at ~30 minutes of hypoxic treatment 
in SMMC-7721 cells and preceded that of HIF-1α. PIM1 
expression gradually increased and leveled off (Figure 
3Bi). The findings suggest that PIM1 may not be a direct 
target of HIF-1α. 
To investigate whether PIM1 protein was subjected 
to ubiquitin-proteasomal degradation, which a common 
post-translational regulatory mechanism of protein 
expression, we treated the HCC cell lines (SMMC-7721 
and MHCC-97L) with a proteasomal inhibitor MG-132 
in normoxia. We found that PIM1 protein level markedly 
increased and was stabilized upon treatment with MG-
132 (Figure 3Bii), suggesting that PIM1 is degraded 
by ubiquitin-proteasomal pathway in normoxia. In 
attempt to further dissect this proteasomal degradation 
mechanism, we examined whether PIM1 protein was 
stabilized upon treatment of prolyl hydroxylase (PHD) 
inhibitor, dimethyloxaloylglycine (DMOG). We found that 
inhibiting PHD activity by DMOG also stabilized PIM1 
protein expression in normoxic condition in SMMC-7721 
and MHCC-97L cells (Figure 3Biii), suggesting that PHD 
may mediate the degradation of PIM1 in normoxia.
Figure 3: PIM1 expression was up-regulated by hypoxia, which was HIF-1α independent. (A) PIM1 expression in HCC cell 
lines and MIHA. N: normoxia (20% O2) H: hypoxia (1% O2). (B) i) PIM1 protein expression was up-regulated at around 30 minutes and 
preceded that of HIF-1α in SMMC-7721. ii) Treatment of SMMC-7721 with proteasome inhibitor MG132 in normoxia stabilized PIM1 
protein. iii) Treatment with propyl hydroxylase inhibitor DMOG in SMMC-7721 and MHCC-97L also stabilized PIM1 protein. 
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suppression of PIM1 reduces Hcc cell 
proliferation and invasion 
Further to the results from in vivo experiments and 
immunohistochemical analysis on human HCC samples, 
we proceeded to consolidate the roles of PIM1 in HCC in 
vitro using the PIM1 stable knockdown clones in SMMC-
7721 cells (Figure 4A). We performed functional assays 
to investigate the effect of modulated PIM1 expression 
on HCC tumor growth and progression under normoxia 
and hypoxia. Silencing PIM1 significantly suppressed the 
proliferation of HCC cells in both normoxic and hypoxic 
conditions with cell proliferation assay (Figure 4B). With 
Matrigel invasion assay, silencing of PIM1 in SMMC-
7721 cells reduced the cell invasive ability under both 
normoxic and hypoxic conditions, with more pronounced 
effects in the latter (p <0.010 in both knockdown clones 
versus p = 0.053 and 0.030 in normoxia) (Figure 4C). The 
results suggest that PIM1 enhances HCC cell invasion, 
and more significantly in hypoxic condition. Since 
we observed that PIM1 was associated with increased 
invasive ability of HCC cells, we attempted to explore 
the correlation between PIM1 expression and epithelial-
mesenchymal transition (EMT) phenotype of HCC cells. 
By Western blotting, we found that knockdown of PIM1 
was associated with decreased protein expression levels of 
fibronectin, β-catenin and vimentin under hypoxia, while 
the effect in normoxia was variable among the 3 markers 
(Figure 4D). These suggest that PIM1 may play an 
important role in activating EMT under hypoxic condition.
Figure 4: silencing of PIM1 inhibited cell proliferation and invasiveness in Hcc (sMMc-7721). (A) Western blot analysis 
of PIM1 expression in PIM1 stable knockdown and NTC clones. (B) Silencing of PIM1 suppressed cell proliferation in both normoxic and 
hypoxia conditions (* NTC vs shPIM1-4; # NTC vs shPIM1-5; */# p<0.05; **/## p<0.01; ***/### p<0.001). (C) Upper panel - Knockdown 
of PIM1 inhibited cell invasiveness in normoxic and hypoxic conditions (20% O2: NTC vs shPIM1-4 p=0.053; NTC vs shPIM1-5 p=0.030; 
1% O2: NTC vs shPIM1-4 p=0.008; NTC vs shPIM1-5 p=0.003). Lower panel - Representative pictures of transwell after staining with 1% 
crystal violet. (D) Expression of epithelial-mesenchymal markers in PIM1 stable knockdown clones shPIM1-4 and shPIM1-5 of SMMC-
7721.
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Knockdown of PIM1 dampens glycolysis of Hcc 
cells
We demonstrated that PIM1 was up-regulated 
by hypoxia in HCC and enhanced the cell proliferation 
and invasiveness of HCC cells especially in a hypoxic 
microenvironment. We then questioned if PIM1 was 
involved in the regulation of glycolysis in HCC cells. By 
glucose uptake assays, we observed an obvious decrease 
in glucose uptake in PIM1 knockdown clones compared 
to NTCs in normoxia. The decrease became even more 
drastic in hypoxia (Figure 5A). The results suggest that 
PIM1 is involved in sustaining both aerobic and anaerobic 
glycolysis of HCC cells.
AKt is a downstream target of PIM1 in Hcc 
glycolysis
Next, we wished to identify the potential 
downstream target of PIM1. Sustaining glycolysis in 
HCC cells may play a pivotal role since energy is required 
for cancer cells to proliferate and invade. Various studies 
have shown that the PI3K/AKT pathway is important in 
mediating glycolysis of cancer cells. Phosphorylation of 
AKT at ser473 position increases AKT activity [18] and 
phosphorylated AKT in turn activates key enzymes in the 
glycolytic pathway including the phosphofructokinase 2 
(PKF2) [18] and hexokinase 2 (HK2) [19]. In addition, 
AKT up-regulates Glucose Transporter 1 (GLUT-1) 
expression in cancer cells [18]. In our experiment with 
Western blotting, knockdown of PIM1 resulted in 
decreased p-AKT and pyruvate kinase M2 (PKM2) levels 
(Figure 5B), while the total AKT level remained static. In 
addition, the transcript levels of both GLUT-1 and PKM2, 
key molecules in the glycolytic pathway, were down-
regulated in PIM1-stable knockdown clones as compared 
with the NTCs (Figure 5C). In view of these findings, we 
proceeded to examine the expression of various markers 
in the glycolytic pathway in the tumor tissues from our in 
vivo mouse model. Coherent with our in vitro data, GLUT-
1 immunoexpression in HCC cells was lower from the 
PIM1 knockdown clones in both subcutaneous inoculation 
(SMMC-7721) and orthotopic implantation (MHCC-97L) 
in mice when compared with NTC (Figures 5D&E). 
On Western blot analysis with the tumor lysates from 
subcutaneous inoculation in mice (SMMC-7721), there 
was a down-regulation of p-AKT (Ser473) and PKM2 
expression in the PIM1 knockdown clone compared with 
NTC (Figure 5F). The results suggest that PIM1 regulates 
HCC glycolysis through AKT and its known downstream 
effectors.
DIscUssION
In this study, we demonstrated the overexpression 
of PIM1 protein in human HCCs in a cohort of clinical 
samples. Furthermore, PIM1 was more frequently 
expressed in extra-hepatic HCC metastases than the 
corresponding primary HCCs. By Western blotting, we 
observed up-regulation of PIM1 in hypoxia in multiple 
HCC cell lines, accompanied by enhanced nuclear 
translocation of the protein. Results from our functional 
assays established a significant role of PIM1 in HCC cell 
proliferation and invasion, particularly under hypoxic 
conditions. The role of PIM1 in HCC growth and 
metastasis was substantiated by in vivo experiments. 
We also provided evidence on the role of PIM1 in 
reprogramming HCC metabolism through glycolysis, and 
demonstrated that AKT is a potential downstream target 
of PIM1. On dissection of the regulatory mechanism of 
PIM1 regulation by hypoxia, we found that it was HIF-1α-
independent and probably through inhibition of the PHD 
activity, hence inhibiting the proteasomal degradation of 
the PIM1 protein. 
Cancer metabolism is an important link between 
tumor microenvironment and tumor progression [20]. 
Cancer cells seize survival benefits through molecular 
mechanisms mechanistically linked to metabolic 
reprogramming, which may include ATP generation, 
evasion of apoptosis, sustained angiogenesis, and 
avoidance of immunosurveillance [20]. Hypoxia promotes 
cancer metastasis partly by altering the metabolism of 
cancer cells including glycolysis [21]. Glycolysis is an 
important mechanism for cancer cells to generate energy 
and sustain proliferation and aggressive features. In 
hypoxia, glycolysis is increased. Cyclical hypoxia leads 
to constitutively active glycolysis even in the presence 
of adequate oxygen, when cancer cells adopt aerobic 
glycolysis (Warburg’s effect) [20, 22, 23]. 
How hypoxia regulates cancer glycolysis has been 
a topic for investigation. In this regard, HIF-1 plays 
an important role in reprogramming cancer cells to 
glycolytic metabolism under hypoxia and in regulating the 
expression of GLUT-1 [24-26]. The co-operation between 
HIF-1 and c-myc in aerobic glycolysis was studied and 
elaborated [27]. p53 is also known to alter the expression 
of GLUT in cancer cells [28]. GLUT-1 is overexpressed 
in HCC tissues and facilitates hepatocarcinogenesis [29, 
30]. Apart from HIF, the PI3K/AKT pathway is crucial 
in regulating the expression of glucose transporters and 
activates some key enzymes in the glycolytic process [18]. 
In our current study, the novel role of PIM1 in cancer 
glycolysis sheds light on how PIM1 sustains HCC growth 
and progression through manipulation of cell metabolism. 
Not being a HIF target, PIM1 enhances AKT-mediated 
glycolysis by activating the phosphorylation of AKT 
and hence its downstream targets to produce energy and 
maintain HCC growth and progression in the hypoxic 
tumor microenvironment.
From the results of our time point experiments and 
those with MG132 treatment, PIM1 protein up-regulation 
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Figure 5: Knockdown of PIM1 suppressed the glycolytic metabolism in sMMc-7721, possibly through the regulation 
of p-AKt. (A) Glucose uptake experiment using 2-NBDG flow cytometry analyses (left panel) and relative glucose uptake (right panel). 
(B) Expression of p-AKT, total AKT and pyruvate kinase M2 (PKM2) in SMMC-7721 stable PIM1 knockdown clones shPIM1-4 and 
shPIM1-5. N: normoxia (20% O2) H: hypoxia (1% O2). (C) Expression of GLUT-1 and PKM2 by qPCR in PIM1 stable knockdown clones 
of SMMC-7721. (D) Immunohistochemical staining of PIM1 and GLUT-1 of HCC tissues in NTC and PIM1 knockdown (KD) clones from 
subcutaneous inoculation (SMMC-7721) and (E) orthotopic implantation (MHCC-97L) of nude mice. (F) Expression of PIM1, p-AKT, 
total AKT and PKM2 of SMMC-7721 tumor lysates from NTC and shPIM1-5 after subcutaneous inoculation in nude mice.
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in hypoxia occurred at post-translational level as quickly 
as 30 minutes upon hypoxic treatment of HCC cells. From 
previous studies, it was suggested that tumor hypoxia can 
be acute or chronic and there has been evidence that acute 
hypoxia (cycle times ranging from 20-60 min) in tumors 
is more readily observed than chronic hypoxia [31-33]. 
In this connection, PIM1, as a quick responder to tumor 
hypoxia, may be capable of facilitating HCC cells to adapt 
to the harsh survival environment and promote tumor 
growth and progression.
Our study has dissected the role of PIM1 in HCC 
and enriched the understanding on the genetic changes 
in response to the hypoxic microenvironment in HCC. 
Apart from regulating HCC proliferation, invasion and 
glycolysis, other potential functional roles of PIM1 in 
HCC may be related to chemoresistance. Hypoxia is also 
known to induce chemoresistance in cancers [21] . In 
pancreatic cancer, PIM1 contributes to chemoresistance 
[13]; hence, it is worthwhile to further explore whether 
PIM1 carries a similar function in HCC, a deadly cancer 
that is notorious for its chemoresistance. 
PIM1 is known to enhance cancer cell survival by 
phosphorylating a number of target genes such as p21waf1, 
p27Kip1 and Cdc25C [34-36]. The PI3K/AKT pathway is 
also known to be crucial in cancer cell survival [37]. The 
potential interaction between PIM1 and AKT regarding 
the regulation of HCC cell proliferation in normoxia and 
hypoxia could possibly be elucidated in future studies. 
From our data, we observed nuclear translocation 
of PIM1 protein under hypoxia in HCC cells. Hence we 
postulate that the nuclear translocation of PIM1 protein 
under hypoxic conditions may help to protect the protein 
from being degraded in the cytoplasm. The nuclear 
fraction might serve as a reservoir of the protein for its 
function as a phosphorylating kinase. However, the 
mechanism for the nuclear-cytoplasmic shuffling remains 
to be elucidated. 
The utility of specific PIM1 inhibitors or 
monoclonal antibodies to treat cancer cells has been 
documented in prostate cancer and leukemia [38-40]. 
Given the significant role of PIM1 in HCC in various 
aspects and since PIM1 is not a direct HIF-1α target, 
specific PIM1 inhibitors might play a unique function 
in intervening HCC metabolism and progression. The 
efficacy of such inhibitors, specifically targeting at tumor 
growth and metastasis as well as cell metabolism, is yet to 
be determined in HCC. 
MAtErIALs AND MEtHODs
Human Hcc samples
Human HCCs and their corresponding non-
tumorous liver samples in the cohort of 56 primary 
HCCs were obtained from patients with liver resection 
between 1992 and 2001 at Queen Mary Hospital, Hong 
Kong and randomly selected for the present study. All 
specimens collected were either snap-frozen in liquid 
nitrogen and stored at -80°C, or fixed in 10% formalin 
for paraffin embedding. Frozen sections from tumorous 
and non-tumorous liver samples were cut and stained 
for histological examination to ensure homogenous 
cell population of tissues. Use of human specimens 
was approved by the institutional review board of the 
University of Hong Kong/Hospital Authority Hong Kong 
West Cluster. Among the 56 patients, 45 were male and 
11 female. The age ranged from 28-82 years. Forty-six 
(82.1%) patients were serum positive for hepatitis B 
surface antigen (HBsAg); 9 were negative. 
cell lines models
Human HCC cell lines BEL-7402, SMMC-7721, 
PLC/PRF/5, MHCC-97L and immortalized normal 
liver cell line MIHA were used. BEL-7402, SMMC-
7721 and MIHA were obtained from Shanghai Institute 
of Cell Biology (Shanghai, China). PLC/PRF/5 was 
purchased from American Type Culture Collection 
(Manassas, VA). MHCC-97L was a gift from Professor 
Z.Y. Tang at Fudan University (Shanghai, China). BEL-
7402 and SMMC-7721 were maintained in Dulbecco’s 
Modified Eagle Minimal Essential Medium (DMEM) 
with high glucose (GIBCO-BRL, Grand Island, NY). 
PLC/PRF/5 was maintained in MEM (GIBCO-BRL) 
with 1mM sodium pyruvate (Sigma Aldrich, St. Louis, 
MO), whereas MHCC-97L and MIHA were maintained 
in DMEM high-glucose with sodium pyruvate. All media 
were supplemented with 10% fetal bovine serum (FBS), 
penicillin at 100 units/mL and streptomycin at 100 µg/
mL (Invitrogen, Gaithersburg, MO). All cell lines were 
cultured at 37°C in a humidified incubator with 5% carbon 
dioxide (CO2). For normoxic conditions, the cells were 
incubated in normal incubator (considered as 20% O2). For 
hypoxic experiments, the cells were cultured in hypoxic 
chamber supplemented with 1% O2. 
Immunohistochemistry 
Immunohistochemical stain was performed on 
formalin-fixed, paraffin-embedded sections using the 
labeled horseradish peroxidase (HRP) method. Paraffin 
sections of 4 µm thick were mounted on poly-L-lysine-
coated slides, deparaffinized and rehydrated in gradient 
alcohol series and distilled water. The slides were 
immersed in 10mM EDTA Tris-HCl antigen retrieval 
buffer (pH9.0) and boiled for 15 minutes, followed by 
slow cooling down at running tap water. Endogenous 
peroxidase activities were quenched by 3% H2O2 for 30 
minutes, followed by rinsing twice in ddH2O and once 
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with 0.1% Tween-20 in TBS. The sections were immersed 
in serum free-protein block solution (Dako, Glostrup, 
Denmark) for 15 minutes and incubated with monoclonal 
antibody against PIM1 (1:250, Abcam, Cambridge, UK), 
GLUT1 (1:500, Abcam), carbonic anhydrase 9 (CA9) 
(1:1000, Abcam), diluted in antibody diluent at 4°C 
overnight. Negative controls were incubated with antibody 
diluent only. The sections were then thoroughly washed 
with 0.1% Tween-20 in TBS five times, and incubated with 
EnvisionTM HRP-conjugated secondary antibody (Dako) 
for 1 hour, followed by washing of five times with 0.1% 
Tween-20 TBS. Positive signals were visualized using 3, 
3’-diaminobenzidine (Dako). Nuclei were counterstained 
with hematoxylin.
Establishment of PIM1 stable knockdown Hcc 
cells
Short-hairpin RNAs (shRNAs) targeting PIM1 
were purchased from Sigma-Aldrich (Mission® 
shRNA bacterial glycerol stock). The clone IDs were 
TRCN0000010118 (clone 1), TRCN0000010117 (clone 
2), TRCN0000010115 (clone 3), TRCN0000196869 
(clone 4) and TRCN0000199011 (clone 5). In short, they 
were indicated as shPIM1-1 to shPIM1-5. To package the 
virus, 2X105 293FT cells (passage 10-12) were seeded 
in 6-well plate 24 hours prior to transfection. Either 
1 µg of shPIM1 or non-target control (NTC) plasmid 
were co-transfected with 1.5 µg of packaging plasmid 
mix (System Biosciences, Mountain View, CA) using 
Lipofectamine 2000 (Invitrogen). The viral supernatant 
was collected 24-hour post-transfection and 400 l were 
used to infect SMMC-7721 and MHCC-97L in polybrene 
(Sigma-Aldrich) supplemented media at 5 µg/mL. After 
48 hours of infection, the infected cells were selected 
with puromycin (Sigma-Aldrich) in gradient manner (5 
µg/mL at 1st week, then 2.5 µg/mL at 2nd week and later 
maintained in 1 g/mL). The success of silencing of PIM1 
in HCC cells was confirmed both normoxic and hypoxic 
conditions using western blotting.
In Vivo subcutaneous xenograft inoculation
The study protocol was approved by the Committee 
of the Use of Live Animals in Teaching and Research 
at the University of Hong Kong. 1X106 of either NTC 
or shPIM1 cells (SMMC-7721 and MHCC-97L) were 
resuspended 100 µl PBS and injected subcutaneously in 
both sides of posterior flanks (right flank: NTC; left flank: 
shPIM1) of 4- to 6-week old male athymic nude mice 
(BALB/CAnN-nu). Tumor sizes were measured every 3 
days by calipers, and tumor volume (mm3) were calculated 
by the formula length X width2 X 0.5. The animals were 
sacrificed after 4 weeks and tumor bulks were harvested. 
All experiments were performed according to the Animals 
(Control of experiments) Ordinance (Hong Kong). The 
experiments were performed twice.
Orthotopic liver implantation of Hcc cells in 
nude mice
Orthotopic implantation was performed as 
previously described [41]. One million of either stable 
NTC or shPIM1 in firefly luciferase-labeled MHCC97L 
were resuspended in 15 μl matrigel and orthotopically 
injected into the left hepatic lobe of 6-week-old male nude 
mice. Tumor growth was monitored by bioluminescent 
approach through injecting 100 mg/kg of D-luciferin 
intraperitoneally into mice 5 minutes before imaging. The 
mice were sacrificed at week 6. The in vivo liver tumor 
growth and ex vivo lung metastasis were recorded using 
IVIS 100 Imaging System (Xenogen, Hopkinton, MA). 
The experiments were performed twice. 
Preparation of protein extracts and western blot 
analyses
The media of cell culture (both normoxic and 
hypoxic samples) were removed and rinsed with ice-
cold phosphate-buffered saline (PBS). Cellular extracts 
were collected on ice using RIPA buffer (0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulfate, 1% Nonidet 
P-40, in PBS) supplemented with 1X protease inhibitor 
cocktail (Roche, Mannheim, Germany). The lysates were 
incubated for 1 hour on ice and centrifuged for 10 minutes 
at 14 000 r.p.m. The supernatants were collected and their 
protein concentrations were determined by the Bradford 
assay (BioRad, Hercules, CA). Protein lysate was 
separated by SDS-polyacrylaminde gel electrophoresis 
(SDS-PAGE) and transferred to polyvinvlidene difluoride 
membrane (Millipore, Billerica, MA) for western blotting 
analyses. Primary antibodies against PIM1 (1:1000, 
Abgent, San Diego, CA), ß-catenin and fibronectin (1: 
2500, BD Transduction Laboratories, San Jose, CA), HIF-
1α (1:1000, Abcam), vimentin, total AKT, phosp-AKT 
(Ser473), pyruvate kinase M2 (PKM2) (1:1000, Cell 
Signaling Technology) ß-actin (1:20000, Sigma-Aldrich), 
lamin-b (1:10000, Santa Cruz Biotechnology, Santa 
Cruz, CA) and GAPDH-HRP (1:50000, Abcam) were 
incubated at 4°C overnight. HRP-conjugated anti-rabbit 
or anti-mouse IgG were used as secondary antibodies 
at 1:5000 where appropriate (GE Healthcare Life 
Sciences, Piscataway, NJ). The signals were visualized 
using the enhanced chemiluminescence method. For 
cell fractionation, fresh cells were washed once with 
ice-cold PBS and centrifuged at 2000 r.p.m. to collect 
the pellets. The cells (1X105) were lysed with 200 µl 
protease-inhibitor supplemented hypotonic buffer and 
incubated on ice for 10 minutes. After adding 2 µl 10% 
NP40 and vortexed briefly, the lysates were spun at 2500 
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r.p.m. for 10 minutes. The supernatant were collected as 
cytoplasmic fraction. The pellets were then washed twice 
with 500 l 0.9% NaCl solution, followed by RIPA buffer 
incubation for 1 hour on ice. The cell debris was removed 
by centrifugation at 14000 r.p.m. for 15 minutes and 
supernatant collected was the nuclear fraction. GAPDH 
and lamin-b expression were served as positive control 
for cytoplasmic and nuclear fractions, respectively. For 
mouse tumor lysates, the tumors from subcutaneous 
inoculation were harvested and rinsed with PBS briefly. 
They were trimmed and snapped frozen using liquid 
nitrogen. The frozen tumors were disrupted, lysed in RIPA 
buffer supplemented with protease inhibitor cocktail and 
phosphatase inhibitor and incubated on ice for four hours. 
The lysates were vortexed vigorously to facilitate the 
lyses. Smooth lysates were collected after centrifugation 
at 14000 r.p.m. for 15 minutes to remove the tissue debris. 
Ubiquitination assay and treatment of DMOG 
(prolyl hydroxylase inhibitor)
The HCC cells were seeded at 2X105 in 6-well plate 
24 hours prior to ubiquitination assay. The cells were 
treated with proteasome inhibitor MG132 (Sigma-Aldrich) 
at gradient concentration (0, 5, 10, 20, 30 µM) for 8 hours. 
DMSO was used as mock control. The protein lysates were 
collected and upregulation of ß-catenin level marked the 
success of the inhibition of proteasomal degradation. The 
experiments were performed twice. Prolyl-4-hydroxylase 
inhibitor dimethyloxalylglycine (DMOG, Sigma-Aldrich) 
was applied to inhibit the activity of prolyl hydroxylase 
(PHD). HCC cells were seeded at 2X105 in 6-well plate 
24 hours prior to DMOG treatment at 100 µM for 24 
hours. The protein expression of HIF-1α served as positive 
control. The experiments were performed twice.
cell proliferation assay
Proliferation of PIM1 knockdown cells was 
determined using cell counting method. Either NTC or 
shPIM1 HCC cells were seeded at 1X104 cells per well 
into 12-well plate in 1 mL. Total number of cells (for 
both normoxic and hypoxic conditions) was counted in 
triplicates each day for five days using Z1 particle counter 
(Beckman Coulter Inc., Brea, CA). The experiments were 
performed three times. 
cell Invasion transwell assay
Invasion Transwell assay was performed as 
previously described [41]. The cells were incubated in 
either normoxic (20% O2) or hypoxic (1% O2) conditions 
for 16 hours prior to the assay. 1X105 cells in serum free 
medium were seeded in upper chamber of Matrigel-coated 
transwell with the lower chamber supplemented with 10% 
serum medium as chemoattractant. The experiments were 
harvested after 16 hours. The transwell membranes were 
fixed with methanol for 1 hour and stained with 1% crystal 
violet. The membranes were cleaned, air-dried, mounted 
on slides and documented. The number of cells invaded 
was counted in 5 random fields. Each experiment was 
performed in duplicates and for four times. 
Glucose uptake assay
Either stable SMMC-7721 of NTC or shPIM1 group 
was seeded at 2X105 in 6-well plate and incubated in 
either normoxic or hypoxic conditions for 24 hours. The 
media were removed and rinsed twice with PBS to remove 
the glucose present in the media. The cells were incubated 
with fluorescent D-glucose analog 2-[N-(7-nitrobenz-2-
oxa-1, 3-diazol-4-yl) amino]-2-deoxyglucose (2-NBDG, 
Invitrogen) at 1:200 diluted in PBS for 15 minutes at 
37°C in dark at either 20% or 1% O2. The cells were 
rinsed twice with ice-cold PBS and scrapped out using 1 
mL PBS. The 2-NBDG uptake reactions were analyzed 
using BD FACSCanto II flow cytometer (BD Biosciences) 
equipped with an argon laser of 488 nm. The results were 
analyzed by the FlowJo 7.6.3 (Tree Star Inc., Ashland, 
OR). The experiments were performed twice.
rNA extraction and quantitative reverse-
transcription polymerase chain reaction (qPcr)
Total RNA was extracted using Trizol reagent (Life 
Technologies) according to manufacturer’s protocol. One 
microgram of RNA was used for cDNA synthesis using 
GeneAmp RNA PCR Kit (Applied Biosystems, Life 
Technologies). Gene expression was examined by Power 
SYBR® Green PCR Master Mix (Applied Biosystems, 
Life Technologies) using the primers indicated in 
(Supplementary Table S3) with Applied Biosystems 
7900HT Fast Real-Time PCR System. Target gene 
expressions were normalized with 18s rRNA level.
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